全球单光子发射电脑断层扫瞄 (SPECT) 市场规模（按产品、应用、最终用户、地区、范围和预测）

单光子发射电脑断层扫瞄 (SPECT) 的市场规模与预测

单光子发射电脑断层扫瞄 (SPECT) 市场规模预计在 2024 年达到 18.8 亿美元，到 2031 年将达到 31.5 亿美元，2024 年至 2031 年的复合年增长率为 6.70%。由于单光子发射电脑断层扫瞄（SPECT）技术的发展以及全球心臟病和癌症发生率的上升，单光子发射电脑断层扫瞄（SPECT）市场正在扩大。此外，对现代诊断设施的投资不断增加以及人们对诊断认识的不断提高正在支持 SPECT 行业的发展。全球单光子发射电脑断层扫瞄 (SPECT) 市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

全球单光子发射电脑断层扫瞄 (SPECT) 市场的定义

单光子发射电脑断层扫瞄 (SPECT) 影像测试可以显示血液如何流向各个器官和组织。它用于识别心血管疾病、癌症、神经系统疾病、中风、癫痫、应力性骨折、感染、脊椎肿瘤等。核子医学影像使用放射性示踪剂和电脑断层扫瞄 (CT) 进行诊断。放射性标记的示踪剂发射出的伽玛射线可被 CT 扫瞄仪侦测到，使医疗专业人员能够研究组织和器官的血流情况。电脑收集伽马辐射发射的数据并将其显示在 CT 扫瞄上。使用这些横截面积可以三维显示大脑和其他器官。

SPECT 使用鎝-99m、铊-201、草酸-123、氟-18 和氙-133 等放射性同位素。透过 SPECT 扫瞄可以检测到流经脑部和脊椎动脉和静脉的血流。研究表明，SPECT 可以比 MRI 或 CT 扫瞄更准确地提供脑损伤影像，因为它可以用于识别受影响区域的血流减少。透过心臟 SPECT 扫瞄检查心臟的血流。心臟中血流不足的区域呈现深色，而血流正常的区域呈现浅色。此外，它还用于诊断未被发现的骨折，例如应力性骨折和胫骨夹板。

全球单光子发射电脑断层扫瞄 (SPECT) 市场概览

由于恶性肿瘤、心血管疾病等严重疾病的患者数量不断增加，市场规模不断扩大。市场主要受快速成长的医疗保健产业所推动。由于人口老化和久坐生活方式导致的疾病增加，预计市场将会扩大。此外，SPECT 机器诊断能力的发展在很大程度上受到双模态和器官特定系统的日益使用的推动。推动市场扩张的另一个因素是冠状动脉疾病的增加。目前，对混合 SPECT 成像系统的需求日益增长。推动市场成长的另外两个因素是放射性药物生产研究的扩大以及公众对该测试类型相对于其他成像技术的多种优势的认识的提高。新型放射性示踪剂的开发和系统设计的持续技术改进正在进一步推动市场扩张。镓-67是肿瘤诊断和分期的黄金标准。 Ga-67 SPECT/CT 混合影像可以准确识别淋巴瘤病变。

Ga-67 是一种常用的发炎成像剂，因为它能够作为金属-转铁蛋白复合物特异性地集中在发炎组织中，然后进一步与转铁蛋白受体结合。许多市场参与者提供柠檬酸镓（GA-67），包括 Lantheus Medical Imaging 和 Mallinckrodt Nuclear。因此，预计市场将在预测期内迅速扩张，不仅由于镓-67 的益处而且由于各种癌症和骨病发病率的上升而呈现出商业潜力。诊断影像设备需要分子同位素，然而，预计预测期内供应和可用性有限将限制全球 SPECT 市场的扩张。例如，鎝和钼是心臟病学中许多 SPECT 程序中使用的两种化学元素，过去几年来多次出现供应短缺。

影响分子同位素供应的另一个因素是，出于安全考虑，一些地区无限期关闭供应同位素的核反应器。产品召回也是困扰全球 SPECT 市场的因素。 SPECT 设备应用于心血管疾病、癌症和脑功能障碍等病变、疾病和器官功能障碍，对重新分期、诊断、分期和追踪产生不利影响。由于产品召回和 SPECT 设备的负面影响，全球 SPECT 市场面临增加收入的问题。

目录

第 1 章。

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 第一次面试
• 资料来源列表

第 4 章单光子发射电脑断层扫瞄 (SPECT) 的全球市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球单光子发射电脑断层扫瞄 (SPECT) 市场（按产品划分）

• 概述
• 独立 SPECT
• 混合 SPECT

第六章 全球单光子 CT 市场（依应用）

• 概述
• 循环系统 肿瘤学
• 一般影像诊断
• 神经病学
• 其他

7. 全球单光子发射电脑断层扫瞄 (SPECT) 市场（按最终用户）

• 概述
• 医院
• 诊断影像中心
• 门诊手术中心

8. 全球单光子发射电脑断层扫瞄 (SPECT) 市场（按区域）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲国家
• 中东和非洲
  • 阿拉伯联合大公国
  • 沙乌地阿拉伯
  • 南非
  • 其他中东和非洲地区

第 9 章。

• 概述
• 各公司的市场排名
• 主要发展策略

第十章 公司简介

• GE Healthcare
• Philips Healthcare
• Siemens Healthineers
• Bruker
• Toshiba Medical（Canon）
• Digirad Corporation
• Esaote
• Invicro
• LambdaSpect
• Mediso Medical Imaging Systems

第 11 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 12 章附录

• 相关研究

Single-Photon Emission Computed Tomography (SPECT) Market Size And Forecast

Single-Photon Emission Computed Tomography (SPECT) Market size was valued at USD 1.88 Billion in 2024 and is projected to reach USD 3.15 Billion by 2031, growing at a CAGR of 6.70% from 2024 to 2031. The Single-Photon Emission Computed Tomography (SPECT) Market is expanding as a result of developments in SPECT technology as well as the rising incidence of cardiac and cancer disorders worldwide. Furthermore, increased investment in modern diagnostic facilities and rising knowledge among people regarding diagnosis are supporting the growth of the SPECT Industry. The Global Single-Photon Emission Computed Tomography (SPECT) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Single-Photon Emission Computed Tomography (SPECT) Market Definition

An imaging examination called a single photon emission computed tomography (SPECT) reveals how blood flows to various organs and tissues. It is utilized to identify cardiovascular problems, cancer, and neurological conditions as well as strokes, seizures, stress fractures, infections, and spinal tumours. A radioactive tracer and computed tomography (CT) are used in a nuclear imaging scan to provide a diagnosis. The radiolabeled tracer allows medical professionals to examine how blood flows to tissues and organs by emitting gamma rays that the CT scanner can detect. Computers gather data from the gamma-ray emissions, which are then shown on the CT cross-sections. The brain and other organs are shown in three dimensions using these cross-sections.

In the SPECT, radioisotopes including technetium-99m, thallium-201, odine-123, fluorine-18, and xenon-133 are used. Blood flow via arteries and veins in the brain and spine can be detected with a SPECT scan. Studies have demonstrated that because it is utilized to identify decreased blood flow to affected regions, it may provide more accurate findings for brain injury than MRI or CT scanning. The blood flow through the heart is examined using cardiac SPECT scans; regions of the heart with inadequate blood flow will look dark, while parts with normal blood flow will appear bright. Furthermore, it is used to diagnose undetected bone fractures, such as stress fractures and shin splints.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Single-Photon Emission Computed Tomography (SPECT) Market Overview

The market is growing because of the increase in individuals suffering from malignancies, cardiovascular diseases, and other critical ailments. The market is primarily driven by the quickly growing healthcare industry. The market is expected to expand because of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment's diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time. Another element driving market expansion is the rise in coronary artery diseases. The need for hybrid SPECT imaging systems is currently increasing. Two other factors that encourage expansion are expanding research into the production of radiopharmaceuticals and increasing public knowledge of the multiple benefits that the testing type has over other imaging techniques. The development of new radiotracers and ongoing technological improvements in system design further boost market expansion. Gallium-67 is the gold standard for tumour diagnosis and staging. Using Ga-67 SPECT/CT in hybrid imaging, lymphoma lesions may be accurately identified.

Ga-67 is a commonly used agent for the imaging of inflammation because of its ability to concentrate not specifically in inflamed tissues as a metal-transferrin complex, followed by further binding to transferrin receptors. A number of market participants, including Lantheus Medical Imaging and Mallinckrodt Nuclear, provides gallium citrate GA-67. Consequently, it is projected that the market would expand rapidly during the forecast period and present business possibilities as a result of the rising frequency of different cancers and bone conditions as well as the benefits of gallium-67. Molecular isotopes are required for diagnostic imaging equipment, however, throughout the anticipated period, a shortage of supply and insufficient availability of these isotopes is predicted to restrain the expansion of the global SPECT market. As an example, there have been multiple supply shortages for the two chemical elements technetium and molybdenum during the past few years, which are often utilized in a significant number of SPECT procedures in cardiology.

An additional factor that has had an impact on the supply of molecular isotopes is the fact that the reactors that provided the isotopes were indefinitely shut down in some regions owing to safety-related concerns. Recalls of products are another factor that is hurting the global market for SPECT. The application of SPECT equipment for lesions, illnesses, and organ dysfunctions, such as cardiovascular disease, cancer, and brain dysfunction, has adverse effects on restaging, diagnosis, staging, and follow-up. The global market for SPECT devices is having problems increasing its revenue because of product recalls and the negative impacts of SPECT devices.

Global Single-Photon Emission Computed Tomography (SPECT) Market Segmentation Analysis

The Global Single-Photon Emission Computed Tomography (SPECT) Market is segmented on the basis of Product, Application, End-User, And Geography.

Single-Photon Emission Computed Tomography (SPECT) Market, By Product

• Standalone SPECT
• Hybrid SPECT

Based on Product, the market is bifurcated into Standalone SPECT and Hybrid SPECT. The Standalone SPECT technology segment accounted for the largest market share in 2022 and is projected to grow at a significant CAGR during the forecast period. The segment's expansion is driven by cancer and heart divisions' increasing use of Standalone SPECT. Gamma ray-based nuclear medicine imaging systems are a type of standalone SPECT. The device can produce high-quality full-body tomographic pictures in real time and detects the gamma-ray emissions from an injected radioisotope to provide images for diagnosis and illness management.

Single-Photon Emission Computed Tomography (SPECT) Market, By Application

• Cardiology
• Oncology
• General Imaging
• Neurology
• Other

Based on Application, the market is bifurcated into Cardiology, Oncology, General Imaging, Neurology, and Other. The segment cardiology accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. Cardiologists use SPECT to see the different parts of the heart's blood flow. By administering a radioactive tracer that has been tagged with gamma cameras, doctors can examine where and how well blood flows into and around the heart. These let doctors determine whether conditions like atherosclerosis, coronary artery disease, hypertension, valvular illnesses like mitral valve prolapse, congenital bicuspid valves caused by an infection in early childhood, etc. have negatively impacted a patient's heart. The segment is expanding as a result of the globalization of cardiovascular diseases as well as increased public knowledge of heart disease diagnostics.

Single-Photon Emission Computed Tomography (SPECT) Market, By End-User

• Hospitals
• Diagnostic Imaging Centers
• Ambulatory Surgical Centers

Based on End-User, the market is segmented into hospitals, diagnostic imaging centers, and ambulatory surgical centers. Hospitals segment accounted for the largest market share in 2022 and is projected to grow at the highest CAGR during the forecast period. The market is expected to expand as a result of ageing populations and the prevalence of ailments brought on by a sedentary lifestyle. The development of SPECT equipment's diagnostic capabilities has also been considerably aided by the rising usage of dual-modality and organ-specific systems throughout time.

Single-Photon Emission Computed Tomography (SPECT) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Single-Photon Emission Computed Tomography (SPECT) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share and is projected to grow at a significant CAGR during the forecast period. The region's big ageing population, high prevalence of cancer cases, and high number of cardiac patients are all driving the growth of the SPECT market there.

Key Players

• The "Global Single-Photon Emission Computed Tomography (SPECT) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Siemens Healthineers, Bruker, Toshiba Medical (Canon), Digirad Corporation, Esaote, Invicro, GE Healthcare, Philips Healthcare, LambdaSpect, Mediso Medical Imaging Systems, MR Solutions, TriFoil Imaging, among others.
• This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In March 2022, Two radiopharmaceuticals in development by GE Healthcare are one for Positron Emission Tomography (PET) and the other is for Single-Photon Release Calculated Tomography imaging. A PET radiopharmaceutical imaging intermediary that intends to help in the assessment of adult patients with purported Parkinsonian disorders, provide research, and enhance patient maintenance was recently announced by the business as having its first patient treated in Phase III clinical study.
• In June 2021, Noria Therapeutics Inc. and PSMA Therapeutics Inc. have entered into a contract with Bayer to be acquired. Through this deal, Bayer will acquire the sole rights to a small molecule targeted at prostate-specific membrane antigen (PSMA) and a differentiated alpha radionuclide investigational drug based on actinium-225.
• In March 2021, IBA (Ion Beam Applications SA and EURONEXT) and NorthStar Medical Radioisotopes LLC declared a partnership to expand technetium-99m (Tc-99m) availability on a worldwide scale. By working together, NorthStar and IBA may develop non-uranium-based Mo-99 for their proprietary Tc-99m Generation Systems (TCM Generation Systems), which are available to businesses outside of the US.
• In November 2020, Prismatic Sensors AB, a Swedish start-up specialising on photon including detectors, was acquired by GE Healthcare, indicating the company's sustained strength in photon counting CT technology. The scientific performance for cancer, cardiology, neurology, and many other clinical CT claims may be greatly improved with this understanding.
• Ace Matrix Analysis
• The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
• Active, Cutting Edge, Emerging, and Innovators.
• Market Attractiveness
• The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Single-Photon Emission Computed Tomography (SPECT) Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
• Porter's Five Forces
• The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Single-Photon Emission Computed Tomography (SPECT) Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Standalone SPECT
• 5.3 Hybrid SPECT

6 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Cardiology
• 6.3 Oncology
• 6.4 General Imaging
• 6.5 Neurology
• 6.6 Other

7 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Diagnostic Imaging Centers
• 7.4 Ambulatory Surgical Centers

8 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 8.5.3 Rest of LATAM
• 8.6 Middle East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 GE Healthcare
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Philips Healthcare
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Siemens Healthineers
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Bruker
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Toshiba Medical (Canon)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Digirad Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Esaote
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Invicro
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Development
• 10.9 LambdaSpect
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Development
• 10.10 Mediso Medical Imaging Systems
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Development

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research